This new Phase III Failure adds up to AstraZeneca’s Troubles

11/08/2016 - 3 minutes

AstraZeneca’s oncology pipeline takes a hit, as one of its Phase III trials failed to meet its primary endpoint. The program targeted advanced non-small lung cancer. It looks like it’s up to immunotherapies now. 

astrazeneca Selumetinib non-small cell lung cancerNow struggling for a while, AstraZeneca has been refocusing on cancer and investing big in new candidates. The strategy hasn’t yet turned AstraZeneca’s luck around, as its half-year reports show its total revenues are down by 3% – really not good.

To make matters worse, it has now released that one of its advanced in lung cancer has failed. With 20 other clinical programs in Phase III on its oncology pipeline alone, it’s not a huge chunk of the company that goes down (unlike in other cases of clinical failures). But it surely doesn’t help.

The ‘offending’ program is a Phase III trial (SELECT-1) to evaluate the efficacy of selumetinib, a small molecule. The study enrolled 510 patients with advanced non-small cell lung cancer (NSCLC) and with a mutation in the KRAS gene.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member